Type 2 Diabetes Trial, Recruiting NCT07463209 Sponsor: University of North Carolina, Chapel Hill Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07463209
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

For the main participant (person with diabetes):

  • Adults who are 65 years of age or older at the time they agree to join the study
  • People who are actively receiving care at a UNC Health or UNC Physicians Network clinic, meaning they have had 2 or more visits in primary care, family medicine, internal medicine, geriatrics, or endocrinology clinics in the past year, and who live within 90 miles of UNC Main Hospital in Chapel Hill, NC
  • People who are currently using any type of insulin
  • People who have not used a continuous glucose monitor (a small wearable device that tracks blood sugar levels) in the past year
  • People who are willing to use a smartphone to view their blood sugar readings through an app
  • People who are fluent in English

For a care partner (optional, someone who supports the main participant):

  • Someone who lives in the same household as the main study participant
  • Someone who is 18 years of age or older
  • Someone who is fluent in English
  • Someone who is willing to attend study sessions alongside the main participant and learn how to better support them in managing diabetes
  • Someone who agrees to have study sessions recorded

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

For the main participant:

  • People who have a clinical diagnosis of dementia (mild cognitive impairment that does not meet the full diagnosis of dementia may still be acceptable — confirm with trial site)
  • People who are currently receiving dialysis
  • People with severe vision or hearing difficulties that would prevent them from using the glucose monitoring device or taking part in group sessions held in person or online
  • People with a significant medical or psychiatric condition, or who are taking a medication, that the study doctor believes could affect their ability to complete the study, or where life expectancy may be less than one year (confirm with trial site)
  • People who are not available for the full 6-week study period, for example due to planned surgery, a procedure, or a vacation, or who are unwilling to follow study procedures
  • People who are not fluent in English
  • People who do not agree to have study sessions recorded

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anna Kahkoska, MD, PhD, University of North Carolina, Chapel Hill

Phone: 919-843-9977

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

CGM Wear Time; CGM Use at 6 Weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov